TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
TC Biopharm (Holdings) ( (TCBPY) ) has issued an announcement.
On November 10, 2025, TC BioPharm (Holdings) plc announced the appointment of Ben Cairns and Michael Magnay from Alvarez and Marsal Europe LLP as interim liquidators. This decision marks a significant shift in the company’s operations, as it plans to deregister its American Depositary Shares and suspend its obligation to file periodic reports with the SEC. This move indicates a potential winding down of operations, which could have considerable implications for stakeholders and the company’s market positioning.
The most recent analyst rating on (TCBPY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on TC Biopharm (Holdings) stock, see the TCBPY Stock Forecast page.
Spark’s Take on TCBPY Stock
According to Spark, TipRanks’ AI Analyst, TCBPY is a Underperform.
TC Biopharm’s overall score is primarily impacted by its weak financial performance, characterized by declining revenues and negative cash flow. Technical analysis indicates bearish momentum, while the absence of valuation metrics and earnings call information limits positive insights. The stock’s financial instability and operational inefficiencies are major concerns.
To see Spark’s full report on TCBPY stock, click here.
More about TC Biopharm (Holdings)
TC BioPharm (Holdings) plc operates in the biotechnology industry, focusing on the development of cell-based therapies. The company is known for its work in immunotherapy, particularly in advancing treatments that harness the body’s immune system to combat diseases.
Average Trading Volume: 9,084
Technical Sentiment Signal: Sell
Current Market Cap: $108.3K
For a thorough assessment of TCBPY stock, go to TipRanks’ Stock Analysis page.